A clinical trial has indicated that a lower-dose version of the South Korean erectile dysfunction drug Mvix, now called AR1001, may slow the progression of Alzheimer’s disease. Conducted over a year with more than 1,500 participants, the trial showed a 31% reduction in mental decline among those not taking other dementia medications. However, the overall results were not statistically significant. The company, AriBio, plans to discuss these findings with the FDA regarding approval.
Key facts
- The trial involved over 1,500 early-stage Alzheimer's patients.
- The drug slowed decline by about 31% in participants not on other dementia medications.
- Overall, the benefit across all participants was not statistically significant.
- Reported side effects included diarrhea, dizziness, and fainting.
- AriBio plans to consult with the FDA about the trial results.
A short AI summary in our own words. The reporting belongs to Daily Wire; we don't reproduce it.